


ONE

RARE DISEASE DRUG'S ACCESS JOURNEY ACROSS THE GLOBE

Vertex, the first company to produce a drug to treat the underlying cause of cystic fibrosis, has fought for fair, and high, prices for its medicines to reflect their value as treatments for the cause of a genetic disease. The company has sought innovative reimbursement agreements for its CF products in various countries – particularly for Orkambi (lumacaftor/inacaftor), a CFTR modulator therapy approved for use in children and adults with CF.



● ORKAMBI APPROVED

- CANADA
- ISRAEL
- BRAZIL
- BELGIUM
- BULGARIA
- CROATIA
- CYPRUS
- CZECH REPUBLIC
- ESTONIA
- FINLAND
- FRANCE
- GREECE
- HUNGARY
- LATVIA
- LITHUANIA
- LUXEMBOURG
- MALTA
- POLAND
- PORTUGAL
- ROMANIA
- SPAIN
- SLOVAKIA
- SLOVENIA
- UK

● ORKAMBI REIMBURSED

- AUSTRALIA
- AUSTRIA
- GERMANY
- ITALY
- NETHERLANDS
- US

● INNOVATIVE REIMBURSEMENT

- DENMARK
- IRELAND
- SWEDEN

75,000 PEOPLE

IN NORTH AMERICA, EUROPE AND AUSTRALIA HAVE CF

1,000

NEW CASES OF CF ARE DIAGNOSED EACH YEAR IN THE US ALONE

INNOVATIVE APPROACH TO NEGOTIATIONS:
VERTEX HAS SUCCESSFULLY AGREED PORTFOLIO-BASED ACCESS FOR ITS CF DRUGS IN THREE REGIONS
READ MORE: BIT.LY/2FGLCQD

70%
OF VERTEX'S REVENUE HAS BEEN INVESTED IN R&D OVER THE LAST FIVE YEARS



\$11BN
INVESTED IN TOTAL SINCE 1989

3

THE NUMBER OF MARKETED MEDICINES IN THE VERTEX CF PORTFOLIO



SEE MORE ONLINE!

For more in-depth analysis and interactive data visit:
<https://bit.ly/2K4Th4v>

SOURCES: Pink Sheet, Scrip, Vertex Pharmaceuticals

